In short: Pick of the Week — "We recommend a Buy on INCY" at ~$129 (52-week range $83.07–$132.60; ~$26.4B cap; +23% YTD, +49% over 12 months; no dividend; beta ~0.41). The structure of the case is a free option: "the market is paying almost nothing for a program that is showing 62% to 75% response rates in one of the most lethal cancers in existence," because "the consensus target of $127.13 is essentially at the current price… a Jakafi-plus-Opzelura base case with limited KRAS credit," while the bull targets (Leerink $155, Canaccord $152, H.C. Wainwright $150) "are the analysts adding in KRAS optionality." Valuation: ~16.5x the 2026 EPS consensus of ~$7.50; EV ~$22.4B (cap less $4B net cash) on FY guidance of $5.2B midpoint = "approximately 4.3x EV/revenue, which is modest for a business growing net sales 40% year-over-year"; on the house's Price/Sales yardstick the headline ~4.4x becomes "~3.6x" EV/sales once the "~$4.5B cash pile" is netted — "for a highly profitable biopharma growing underlying product sales at double digits with a deep Phase III pipeline… pretty attractively valued," the discount "largely reflects the fear that its newer products won't replace its legacy ones." The base business: Jakafi (myelofibrosis, polycythemia vera, GVHD) at $817M in Q2 (+7% YoY), "on pace for approximately $3.2 billion annually, shared with Novartis outside the U.S." — "the cash cow"; Opzelura at $450M — "the growth driver that has consistently outrun consensus estimates," the first and still only FDA-approved treatment that "can restore skin color in vitiligo patients," where "each approved indication adds a new patient population at minimal marginal cost"; H&O portfolio $204M+ (Niktimvo, Monjuvi/Minjuvi, Zynyz). Q2 2026 (Jul 28): revenue $1.67B +38%, net sales $1.49B +40%, EPS $3.09 vs $1.84 (68% beat; ~55% operational after a $246M non-cash Medicaid rebate settlement), FY2026 net sales guided to $5.13–$5.26B, EPS consensus ~$7.50 (+106% YoY est.). Pipeline: 10 Phase 3 studies, "four anticipated approvals in the next 12 months" as the near-term catalysts, povorcitinib positive Phase 3 in vitiligo, NDA accepted in hidradenitis suppurativa; $4.0B+ net cash, no meaningful debt. The KRAS G12D option: pancreatic ductal adenocarcinoma has five-year survival "below 12% for all stages, below 3% for metastatic disease," KRAS mutated in ~90% of cases and "considered undruggable for three decades"; G12D is ~40% of pancreatic cancers. DAWN-303 EU registry: with GemNabP 62.5% response / 95.8% disease control; with mFOLFIRINOX 75% / 100%, against first-line chemo alone at "20% to 30%" — "less of a lottery ticket and more of a practice-changing drug." RBC says the ESMO update is "likely to be very competitive"; the October oral presentation "will confirm or challenge this reading," and if it fails "Incyte absorbs it from a diversified multi-franchise platform rather than a binary single-asset position." Bear case, argued: the Jakafi patent cliff — US compound protection expires 2028, formulation patents "potentially" extending to 2033, on ~55% of current net sales, with the risk that "Opzelura and the new product launches grow too slowly to offset genericization"; the KRAS read is "a small interim cut with maturity limitations" and "Phase 1 combination data has misled markets before"; durability and long-term safety data "are also not yet available"; and "the stock at $129 with 49% 12-month appreciation is not a margin-of-safety purchase" — an ESMO miss or a regulatory stumble "hits a stock priced for continued execution with limited consensus upside buffer." Entry/technicals: "we are a bit late to this one from a timely breakout signal standpoint" (the signal fired "late last year when it initially broke into the $90s"), but the advance since "hasn't been excessive" and "has been earnings-driven"; it is "somewhat stretched over the 200-day moving average," so "a retracement back to $110 or so would not be at all surprising. More conservative investors might want to hold off to see if that happens." Next earnings October 27, 2026. No portfolio tables published with this issue.
Incyte is a mid-sized drug company with two products that pay the bills. Jakafi is a pill for several blood-marrow diseases and is the leading drug of its type — about $817 million of sales last quarter, roughly $3.2 billion a year (Novartis sells it outside the US and takes a share). Opzelura is a skin cream, and it is the only approved medicine that can bring the colour back to skin in patients with vitiligo; it did $450 million last quarter and keeps beating expectations. The company is profitable, has more than $4 billion of cash and essentially no debt, and has ten late-stage trials running with four new approvals expected within a year.
The catch — and the reason the stock is cheap — is a patent cliff: Jakafi's main US patent runs out in 2028, after which cheap generic copies can take the business. Jakafi is about 55% of sales today, so the market is worried the newer drugs won't grow fast enough to replace it. That fear is why you can buy the whole company for about 16.5 times next year's earnings, or roughly 4.3 times its sales once you subtract the cash — modest for a business whose sales are growing 40%.
Hay's actual argument is about what you get thrown in for nothing. Incyte has an experimental drug aimed at KRAS G12D, a genetic fault behind about 40% of pancreatic cancers — a disease where fewer than one in ten patients is alive after five years and where, for thirty years, this target was considered impossible to hit. In an early European study the drug shrank tumours in 62.5% to 75% of patients depending on the chemotherapy it was paired with, versus 20–30% for chemotherapy alone. Wall Street's average price target ($127) is basically today's price, which tells you analysts are valuing Jakafi and Opzelura and giving the cancer drug roughly zero credit; the few who do add it in are at $150–155. So you are paying a fair price for the existing business and getting a potentially enormous drug as a free option — one that, if it fails at the October ESMO conference, the company can absorb because it isn't a one-drug bet.
The honest caveats, which Haymaker states itself: the cancer data is an early, small read and early data has fooled markets before; the stock is already up 49% in a year, so this is not a bargain-basement entry; and it is stretched above its 200-day average, so "a retracement back to $110 or so would not be at all surprising" — more cautious buyers are told to wait for that dip. This is a Buy and a sleeve-builder — the fourth healthcare name added since June, after MDT, DGX and GILD — on the view that healthcare and biotech are entering a multi-year recovery.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.